trans-2-pyrrolidinyl-3-(N-methyl-3',4'-dichlorophenylacetamido)-1,2,3,4-tetrahydroanthracene | 133970-14-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: trans-2-pyrrolidinyl-3-(N-methyl-3',4'-dichlorophenylacetamido)-1,2,3,4-tetrahydroanthracene
• 英文别名: 2-(3,4-Dichloro-phenyl)-N-methyl-N-(3-pyrrolidin-1-yl-1,2,3,4-tetrahydro-anthracen-2-yl)-acetamide；2-(3,4-dichlorophenyl)-N-methyl-N-[(2R,3R)-3-pyrrolidin-1-yl-1,2,3,4-tetrahydroanthracen-2-yl]acetamide
• CAS: 133970-14-6
• 化学式: C₂₇H₂₈Cl₂N₂O
• 分子量: 467.438
• InChiKey: QZPVBDWKSMUGSH-CLJLJLNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  trans-2-hydroxy-3-pyrrolidinyl-1,2,3,4-tetrahydroanthracene 在 甲基磺酰氯 、 三乙胺 、 N,N'-羰基二咪唑 作用下， 反应 41.5h， 生成 trans-2-pyrrolidinyl-3-(N-methyl-3',4'-dichlorophenylacetamido)-1,2,3,4-tetrahydroanthracene
  参考文献：
  名称：

  Naphtho and benzo analogs of the .kappa. opioid agonist trans-(.+-.)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide

  摘要：

  Further elaboration on the structure-activity relationships in our U-50,488 series has revealed that benzologation of this cyclohexane-1,2-diamine derivative provides compounds which either maintain the interaction with the kappa-receptor (e.g. compounds 3a and 5a in the phenylacetamido series) or eliminate the mu-receptor mediated analgesia (e.g. compounds 3-6 in the benzamido series). Naphthologation also caused the elimination of mu-receptor mediated analgesia (e.g. compounds 17a and 17b).

  DOI：

  10.1021/jm00110a021

文献信息

• Naphtho and benzo analogs of the .kappa. opioid agonist trans-(.+-.)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide
  作者：Jeremiah P. Freeman、Eric T. Michalson、Stan V. D'Andrea、Lubomir Baczynskyj、Philip F. VonVoigtlander、R. A. Lahti、Martin W. Smith、Charles F. Lawson、Terrence A. Scahill

  DOI：10.1021/jm00110a021

  日期：1991.6

  Further elaboration on the structure-activity relationships in our U-50,488 series has revealed that benzologation of this cyclohexane-1,2-diamine derivative provides compounds which either maintain the interaction with the kappa-receptor (e.g. compounds 3a and 5a in the phenylacetamido series) or eliminate the mu-receptor mediated analgesia (e.g. compounds 3-6 in the benzamido series). Naphthologation also caused the elimination of mu-receptor mediated analgesia (e.g. compounds 17a and 17b).